Counseling for Insulin Icodec: A Proposed Practitioner's Guide.

IF 3.8 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2024-07-01 Epub Date: 2024-05-14 DOI:10.1007/s13300-024-01600-y

Sanjay Kalra, Saptarshi Bhattacharya, Nitin Kapoor

引用次数: 0

Abstract

Despite insulin being a lifesaving medication, insulin distress, insulin hesitancy, and insulin inertia remain oft-repeated themes in diabetes discourse. The current model lists three issues: temperament, troublesomeness, and technicality, which contribute to insulin perceptions. Therapeutic patienteducation (TPE), value-added therapy (VAT), and medication counseling are concepts that assist in optimizing insulin perceptions. Insulin icodec is a basal insulin with a half-life of 196 h and a once-weekly or circaseptan frequency of administration. Insulin icodec reduces the frequency of basal insulin administration to one-seventh, which along with the lower requirement of glucose monitoring, reduces the burden of plastic and ancillary supply disposal. Because of its unique frequency of injection, insulin icodec usage requires appropriate counseling and education. This reader-friendly counseling guide helps practitioners offer VAT, as well as TPE while prescribing icodec and other insulins.

查看原文本刊更多论文

胰岛素 Icodec 咨询：建议从业者指南》。

尽管胰岛素是一种救命药物，但胰岛素困扰、胰岛素犹豫不决和胰岛素惰性仍是糖尿病讨论中经常重复的主题。目前的模式列出了三个问题：脾气、麻烦和技术性，这些都是造成胰岛素认知的原因。治疗性患者教育（TPE）、增值疗法（VAT）和药物咨询是有助于优化胰岛素认知的概念。胰岛素 icodec 是一种半衰期为 196 小时的基础胰岛素，给药频率为每周一次或循环给药。胰岛素 icodec 可将基础胰岛素的给药频率降低到七分之一，同时降低了葡萄糖监测的要求，减轻了塑料和辅助用品处理的负担。由于其独特的注射频率，胰岛素 icodec 的使用需要适当的咨询和教育。这本便于阅读的咨询指南可帮助医生在开具 icodec 和其他胰岛素处方时提供增值税和 TPE。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.